Fair Money & Economic Opportunity

Oxford Biomedica operates in the gene and cell therapy sector, not financial services. Consequently, it does not offer lending, deposit, or other financial products to consumers. All KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, and fair lending compliance, are not applicable to its core business. Evidence provided pertains to internal employee diversity and inclusion, wellbeing initiatives (like learning vouchers and webinars on stress/debt management for employees)

, or scientific data management , which falls outside the scope of financial services for external customers.

Fair Trade & Ethical Sourcing

No specific quantitative data was provided in the articles to assess the company against the defined KPIs for Fair Trade & Ethical Sourcing. While the company states it conducts business in accordance with the UK Modern Slavery Act 2015

, has a Supplier Code of Conduct , and asks counterparties to confirm compliance with anti-slavery laws , there is no information on the percentage of fair-trade certified spend, supplier audit frequency, number of forced or child labour incidents, supply chain traceability coverage, remediation speed, percentage of contracts with enforceable ethical clauses, spend on high-risk materials, or supplier diversity spend.

Honest & Fair Business

Oxford Biomedica has a comprehensive whistleblowing policy that encourages reporting misconduct in confidence and without fear of retaliation.

It provides a 24-hour whistleblowing service and an anonymous confidential reporting channel for all employees , with procedures in place to protect whistleblowers. All employees are trained on whistleblowing , and concerns are thoroughly investigated with disciplinary action taken where necessary. The company also has an anti-bribery and corruption policy, compliant with the UK Bribery Act 2010 and other relevant overseas legislation. This policy was redrafted for rollout to OXB US and OXB France. In 2024, all UK employees were required to complete anti-bribery training annually through an online learning portal , and effective measures for monitoring compliance at all sites are planned for rollout in 2025.

No War, No Weapons

Oxford Biomedica is a gene and cell therapy company focused on healthcare and pharmaceutical industries, indicating no core business in defense or arms. Consequently, there is no revenue from arms contracts, no defense assets to divest, and no direct exposure to controversial weapons. The company also has no need for ethical red lines related to weapons manufacturing. For sales to embargoed regimes, the Group complies with the UK Export Control Act 2002 and the US Export Controls Act 2018, and maintains a list of countries, including sanctioned ones, to which it does not generally sell.

The company aims to prevent the development of weapons of mass destruction through its export controls. The ESG Committee provides regular progress reports on ESG commitments to the Corporate Executive Team quarterly and to the Board.

Planet-Friendly Business

Oxford Biomedica reported 4,021 tCO2e in Scope 1, 2, and selected Scope 3 emissions for its UK operations in 2021, an increase from approximately 3,994 tCO2e in 2020.

The company aims to gain affiliation with an external agency like SBTi for its sustainability plan and is looking to develop a strategy to reach net-zero by 2040. The Group states it complies with all environmental regulations. Oxford Biomedica supports the TCFD framework and has made disclosures consistent with its four recommendations and 11 disclosures. However, its assessment of climate change impact is described as part of its normal risk management process. The company has used BREEAM for its Windrush Innovation Centre building during planning and construction phases. It has increased recycling efforts, including a 61% reduction in Virkon waste and recycling coffee pods, and aims to increase overall recycling by 5%. Used wooden pallets are donated to a local social venture.

Zero Waste & Sustainable Products

Oxford Biomedica has implemented several waste reduction initiatives, including moving processes to paperless, which saved approximately 10,000 sheets of paper

, and a revised waste process that resulted in a 61% reduction in Virkon waste (approximately 18,500L less than 2020) . Other initiatives include increased recycling efforts through installing compactors , a coffee pod recycling scheme , donating used wooden pallets , projects launched in 2021 to reduce supply chain waste by developing reusable transportation containers , and a waste awareness day . The company operates under an environmental permit that requires applying the waste hierarchy and minimizing environmental impact , including proper storage of hazardous waste in containment like a bunded 50kl alkaline wastewater tank . While a 2021 ESG target to reduce the overall volume of hazardous liquid waste was not met , the company states it complies with all environmental regulations, including those related to waste disposal . Oxford Biomedica has quantitative waste reduction targets, such as a 2022 ESG objective to increase recycling by 5% and a key target to reduce packaging materials .